Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID‐19

Since December 2019, coronavirus disease (COVID‐19) has rapidly swept the world. So far, more than 30 million people have been infected and nearly one million have died. Although the world is still in the stage of COVID‐19 pandemic, the treatment of new cases and critically ill patients is the focus of the current work. However, COVID‐19 patients lead to pulmonary fibrosis, such a serious threat to the prognosis of complications were also worthy of our attention. First of all, we proposed the possible mechanism of pulmonary fibrosis caused by SARS‐CoV‐2, based on the published data of COVID‐19 ((i) Direct evidence: pulmonary fibrosis was found in autopsy and pulmonary puncture pathology. (ii) Indirect evidence: increased levels of fibrosis‐related cytokines[transforming growth factor [TGF]‐ β, tumor necrosis factor [TNF]‐ α, interleukin [IL]‐6, etc] in peripheral blood of severe patients.) What is more, we summarized the role of three fibrosis‐related signaling pathways (TGF‐ β signal pathway, WNT signal pathway and YAP/TAZ signal pathway) in pulmonary fibrosis. Finally, we suggested the therapeutic value of two drugs (pirfenidone and nintedanib) for idiopathic pulmonary fibrosis in COVID‐19‐induced pulmonary fibrosis. Highlights Severe COVID‐19 patients should pay attention to secondary pulmonary fibrosis after lung injury TGF‐ β signal pathway, WNT signal pathway and YAP/TAZ signal pathway participated in pulmonary fibrosis caused by COVID‐19. 3. Pirfenidone and Nintedanib may be the effective drugs for the treatment of pulmonary fibrosis caused by COVID‐19.